Launched on 6 October 2026Last updated on

DAPT duration, de-escalation to clopidogrel and CYP2C19 genotyping

Balances bleeding risk (ARC-HBR, PRECISE-DAPT, bleeding on DAPT, oral anticoagulation) against thrombotic risk (complex PCI: left main, last patent vessel, two-stent bifurcation, CTO, ≥ 3 stents or lesions, 3 vessels, > 60 mm of stent; prior stent thrombosis, recurrent MI, diabetes, CKD, PAD, diffuse disease) to set the DAPT duration after ACS or elective PCI. Decides whether and when to de-escalate from ticagrelor or prasugrel to clopidogrel (not unguided in the first 30 days after ACS; genotype-guided earlier; not in CYP2C19 loss-of-function carriers), gives the switching doses, flags when CYP2C19 genotyping is worth doing (clopidogrel after left main or other high-risk PCI, early guided de-escalation, OAC after complex PCI, stent thrombosis on clopidogrel) and shows ESC 2023 ACS / 2024 CCS beside ACC/AHA 2025 ACS / 2023 chronic coronary disease recommendations.

Upload a report, lab sheet or echo picture to fill this calculator automatically.
Indication for PCI
Time since PCI
Current P2Y12 inhibitor
Bleeding side
Use ARC-HBR or PRECISE-DAPT
Thrombotic side: complex PCI
ESC 2023 / 2024 high thrombotic risk
Thrombotic side: clinical
CYP2C19 genotype
Loss-of-function alleles *2, *3; gain *17
ACS · < 1 month after PCI · ticagrelor
Standard risk
DAPT 12 months (default), or 3–6 months then P2Y12 inhibitor monotherapy if event-free
Decision guide
  • No high-risk features ticked
    Follow the default duration; reassess bleeding and ischaemic risk at every visit and at 12 months (DAPT score).
De-escalation to clopidogrel
  • No reason to de-escalate
    Continue the potent P2Y12 inhibitor for the planned course. De-escalation is an option for bleeding risk, bleeding, side effects (ticagrelor dyspnoea), the need for OAC, or cost.
CYP2C19 genotyping
  • Not needed routinely
    Neither ESC nor ACC/AHA recommends routine genotyping. It helps when clopidogrel is planned after high-risk PCI (left main, last vessel, 2-stent bifurcation, long or multiple stents), for early guided de-escalation after ACS, with OAC after complex PCI, after stent thrombosis on clopidogrel, and in East or South Asian patients.
DAPT duration
ESC
  • Default: DAPT 12 months
    IESC 2023 ACS
    Aspirin plus prasugrel or ticagrelor (clopidogrel if they are unavailable, not tolerated or contraindicated).
  • Event-free at 3–6 months, not high ischaemic risk: single antiplatelet
    IIaESC 2023 ACS
    Preferably the P2Y12 inhibitor.
  • High bleeding risk: monotherapy after 1 month
    IIbESC 2023 ACS
    Aspirin or P2Y12 inhibitor monotherapy after 1 month of DAPT.
  • De-escalation (prasugrel / ticagrelor → clopidogrel) as an alternative
    IIbESC 2023 ACS
  • No de-escalation in the first 30 days after ACS
    IIIESC 2023 ACS
  • OAC: triple therapy ≤ 1 week, then OAC + clopidogrel up to 12 months
    IESC 2023 ACS
    Up to 1 month of triple therapy when ischaemic risk is high.
  • High ischaemic risk, no high bleeding risk: extended second antithrombotic
    IIaESC 2023 ACS
    Beyond 12 months (ticagrelor 60 mg twice daily, prasugrel, clopidogrel, or rivaroxaban 2.5 mg twice daily).
ACC/AHA
  • Default: DAPT at least 12 months
    IACC/AHA 2025 ACS
    Ticagrelor or prasugrel preferred over clopidogrel after PCI for ACS.
  • Tolerated DAPT ≥ 1 month: transition to ticagrelor monotherapy
    IACC/AHA 2025 ACS
    Stop aspirin to reduce bleeding.
  • High bleeding risk: single antiplatelet after 1 month of DAPT
    IIaACC/AHA 2025 ACS
  • De-escalation to clopidogrel may be reasonable to reduce bleeding
    IIbACC/AHA 2025 ACS
  • OAC: stop aspirin after 1–4 weeks, continue OAC + P2Y12 inhibitor (clopidogrel)
    IACC/AHA 2025 ACS
Print / Save PDF: opens the print dialog with a table of the inputs and result; choose Save as PDF to keep a file. Made on this device only; nothing is uploaded.